The therapeutic target for COVID-19 remains unclear, while study has shown that the novel coronavirus infects alveolar type II cells through the mechanism of interaction of the spike protein with the human renin and type II angiotensin converting enzyme (ACE2), leading to pneumonia [7], therefore, genes co-expressed with ACE2 are considered as potential therapeutic targets on COVID-19 [8]. This evidence concerns the gene ACE2 and COVID-19.